Gustav Buescher

Gustav Buescher

Auto-generated profile, based on publicly available information

Gustav Buescher

I. Department of Medicine, University Medical Center Hamburg-Eppendorf

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Hepatology
Verified
Journal Article
Open access
TMThomas Marjot
Thomas Marjot
GBGustav Buescher
Gustav Buescher
MSMarcial Sebode
Marcial Sebode
EBEleanor Barnes
Eleanor Barnes
ABA. Sidney Barritt
A. Sidney Barritt
ALAnsgar W. Lohse
Ansgar W. Lohse
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the globe. However, little is known about the disease course in patients with autoimmune hepatitis (AIH). Data for patients with AIH and SARS-CoV-2 infection were combined from 3 international reporting registries and outcomes were compared to those in patients with chronic liver disease of other aetiology (non-AIH CLD) and to patients without liver disease (non-CLD). Between 25th March and 24th October 2020, data were collected for 932 patients with CLD and SARS-CoV-2 infection including 70 with autoimmune hepatitis (AIH). Fifty-eight (83%) patients with AIH were taking ≥1 immunosuppressive drug. There were no differences in rates of major outcomes between patients with AIH and non-AIH CLD, including hospitalization (76% vs. 85%; p = 0.06), intensive care unit admission (29% vs. 23%; p = 0.240), and death (23% vs. 20%; p = 0.643). Factors associated with death within the AIH cohort included age (odds ratio [OR] 2.16/10 years; 1.07–3.81), and Child-Pugh class B (OR 42.48; 4.40–409.53), and C (OR 69.30; 2.83–1694.50) cirrhosis, but not use of immunosuppression. Propensity score matched (PSM) analysis comparing patients with AIH with non-AIH CLD demonstrated no increased risk of adverse outcomes including death (+3.2%; -9.2%–15.7%). PSM analysis of patients with AIH vs. non-CLD (n = 769) demonstrated increased risk of hospitalization with AIH (+18.4%; 5.6–31.2%), but equivalent risk of all other outcomes including death (+3.2%; -9.1%–15.6%). Patients with AIH were not at increased risk of adverse outcomes despite immunosuppressive treatment compared to other causes of CLD and to matched cases without liver disease. Little is known about the outcomes of COVID-19 in patients with autoimmune hepatitis (AIH), a rare chronic inflammatory liver disease. This study combines data from 3 large registries to describe the course of COVID-19 in this patient group. We show that AIH patients do not appear to have an increased risk of death from COVID-19 compared to patients with other forms of liver disease and compared to patients without liver disease, despite the use of medications which suppress the immune system.

8 October 2020 in Liver International
Verified
Journal Article
Open access
PDF file
GBGustav Buescher
Gustav Buescher
AOAnn‐Kathrin Ozga
Ann‐Kathrin Ozga
ELEva Lorenz
Eva Lorenz
Sven PischkeSven Pischke
Sven Pischke
JMJürgen May
Jürgen May
THThomas Horvatits
Thomas Horvatits
Background and Aims: Hepatitis E is an infectious disease of the liver caused by the hepatitis E virus (HEV). Immunocompromised patients present a particular risk group, as chronification of hepatitis E leading to life‐threatening cirrhosis occurs when these patients are infected. Therefore, this study aims to estimate and compare the anti‐HEV seroprevalence and the rate of HEV RNA positivity in transplant recipients and patients with human immunodeficiency virus (HIV).Methods: This systematic review and meta‐analysis involved a literature search (PubMed, Scopus; 1,138 studies) including 120 studies from 1996 to 2019, reporting anti‐HEV seroprevalence and/or HEV‐RNA positivity. Statistical analysis was performed using a linear mixed‐effects meta regression model.Results: Anti‐HEV seroprevalence in 14 626 transplant recipients ranged from 6% (95% CI: 1.9‐17.2) to 29.6% (95% CI: 21.6‐39.) in different commercially available assays and did not differ significantly compared to 20 825 HIV positive patients (range: 3.5% (95% CI: 0.9‐12.8) – 19.4% (95% CI: 13.5‐26.9). In contrast, HEV‐RNA positivity rate was significantly higher in transplant recipients than in HIV positive patients (1.2% (95% CI: 0.9‐1.6) vs 0.39% (95% CI: 0.2‐0.7); P‐value = 0.0011).Conclusion: Anti‐HEV seroprevalence did not differ significantly between transplant recipients and HIV positive patients. Interestingly, rates of HEV‐RNA positivity, indicating ongoing infection, were significantly higher in transplant recipients. These findings demonstrate that transplant patients have an elevated risk of chronic infection in comparison to HIV patients at comparable risk of HEV‐exposure.

4 May 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
MJMarianne Hørby Jørgensen
Marianne Hørby Jørgensen
MCMara Cananzi
Mara Cananzi
GBGustav Buescher
Gustav Buescher
MSMarianne Samyn
Marianne Samyn
RBRuth De Bruyne
Ruth De Bruyne

18 July 2023 in medRxiv
Verified
Preprint
Open access
PDF file
LKLorenz Kocheise
Lorenz Kocheise
IPIgnazio Piseddu
Ignazio Piseddu
JVJoscha Vonderlin
Joscha Vonderlin
ETEric T Tjwa
Eric T Tjwa
GBGustav Buescher
Gustav Buescher
KSKornelius Schulze
Kornelius Schulze
Background: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune-related adverse events (irAE) are a frequent concern in clinical practice. The safety profile of ICI for the treatment of malignancies in patients diagnosed with autoimmune liver disease (AILD) remains unclear. Due to this uncertainty, these patients were excluded from ICI clinical trials and ICI are withheld from this patient group. In this retrospective multicenter study, we assessed the safety of ICI in patients with AILD. Methods: We contacted tertiary referral hospitals for the identification of AILD patients under ICI treatment in Europe via the European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Fourteen centers contributed data on AILD patients with malignancies being treated with ICI, another three centers did not treat these patients with ICI due to fear of irAEs. Results: In this study, 22 AILD patients under ICI treatment could be identified. Among these patients, 12 had primary biliary cholangitis (PBC), five had primary sclerosing cholangitis (PSC), four had autoimmune hepatitis (AIH), and one patient had an AIH-PSC variant syndrome. Eleven patients had hepatobiliary cancers and the other 11 patients presented with non-hepatic tumors. The applied ICIs were atezolizumab (n=7), durvalumab (n=5), pembrolizumab (n=4), nivolumab (n=4), spartalizumab (n=1), and in one case combined immunotherapy with nivolumab plus ipilimumab. Among eight patients who presented with grade 1 or 2 irAEs, three demonstrated liver irAEs. Cases with grades ≥ 3 irAEs were not reported. No significant changes in liver tests were observed during the first year after the start of ICI. Conclusions: This European multicenter study demonstrates that PD-1/PD-L1 inhibitors appear to be safe in patients with AILD. Further studies on the safety of more potent dual immune checkpoint therapy are needed. We conclude that immunotherapy should not categorically be withheld from patients with AILD.